---
layout: default
title: Isosorbide Dinitrate
description: "Isosorbide Dinitrate çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 95
evidence_level: L2
indication_count: 10
---

# Isosorbide Dinitrate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Isosorbide Dinitrateï¼šå¾ ç‹¹å¿ƒç—‡ åˆ° è‚ºé«˜å£“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Isosorbide Dinitrate å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Isosorbide dinitrateï¼ˆäºŒç¡é…¸ç•°å±±æ¢¨é…¯ï¼‰æ˜¯ä¸€ç¨®æœ‰æ©Ÿç¡é…¸é…¯é¡è¡€ç®¡æ“´å¼µåŠ‘ï¼Œç”¨æ–¼é é˜²å’Œæ²»ç™‚ç‹¹å¿ƒç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**è‚ºé«˜å£“ (pulmonary hypertension)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰è¶…é **20 ç¯‡æ–‡ç»**æ”¯æŒæ­¤é æ¸¬ï¼Œè­‰æ“šç­‰ç´šé«˜ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é é˜²åŠæ²»ç™‚ç‹¹å¿ƒç—‡ç™¼ä½œã€å† ç‹€å‹•è„ˆä¸å…¨ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | è‚ºé«˜å£“ (pulmonary hypertension)ã€è„«é«®ç—‡ (alopecia) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% (è‚ºé«˜å£“) |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Explore |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Isosorbide dinitrate é€šéé‡‹æ”¾ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰æ¿€æ´»è¡€ç®¡å¹³æ»‘è‚Œç´°èƒä¸­çš„é³¥è‹·é…¸ç’°åŒ–é…¶ï¼Œå°è‡´ç’°ç£·é…¸é³¥è‹·ï¼ˆcGMPï¼‰æ¿ƒåº¦å‡é«˜ï¼Œé€²è€Œå¼•èµ·è¡€ç®¡èˆ’å¼µã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>


**æ©Ÿè½‰æ”¯æŒï¼š**
- NO æ˜¯è‚ºè¡€ç®¡èˆ’å¼µçš„é‡è¦ä»‹è³ª
- ç¡é…¸é…¯é¡è—¥ç‰©å¯é™ä½è‚ºå‹•è„ˆå£“åŠ›
- ä¸»è¦ä½œç”¨æ–¼å®¹é‡è¡€ç®¡ï¼ˆéœè„ˆï¼‰ï¼Œæ¸›å°‘å¿ƒè‡Ÿå‰è² è·
- è¼ƒé«˜åŠ‘é‡ä¹Ÿå¯æ“´å¼µå‹•è„ˆï¼ŒåŒ…æ‹¬è‚ºå‹•è„ˆ

æ­¤é æ¸¬å…·æœ‰å …å¯¦çš„è—¥ç†å­¸åŸºç¤ï¼Œä¸”æœ‰å¤§é‡è‡¨åºŠæ–‡ç»æ”¯æŒã€‚

### è‡¨åºŠè©¦é©—

é›–ç„¡å°ˆé–€é‡å°è‚ºé«˜å£“çš„å¤§å‹ RCT ç™»è¨˜ï¼Œä½†æ–‡ç»é¡¯ç¤ºå¤šé …ç ”ç©¶å·²æ¢è¨æ­¤æ‡‰ç”¨ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [39164577](https://pubmed.ncbi.nlm.nih.gov/39164577/) | 2025 | Journal Article | Heart and vessels | Bolus ISDN æ³¨å°„å¯é™ä½ mPAPï¼Œåœ¨å¾Œæ¯›ç´°è¡€ç®¡æ€§è‚ºé«˜å£“æ•ˆæœè¼ƒä½³ |
| [6423015](https://pubmed.ncbi.nlm.nih.gov/6423015/) | 1984 | Comparative Study | Bull Eur Physiopathol Respir | ISDN å’Œ NTG å‡å¯é™ä½ COPD æ‚£è€…è‚ºå‹•è„ˆå£“ |
| [28810603](https://pubmed.ncbi.nlm.nih.gov/28810603/) | 2017 | Journal Article | Exp Ther Med | æ°£ç®¡å…§ ISDN å¯æ”¹å–„å¿ƒè‚Œæ¢—å¡å¾Œå¿ƒè¡°å¤§é¼ çš„è‚ºå‹•è„ˆå£“å’Œå¿ƒå®¤é‡å¡‘ |
| [373940](https://pubmed.ncbi.nlm.nih.gov/373940/) | 1979 | RCT | Clin Pharmacol Ther | å£æœ ISDN æœ‰æ•ˆé™ä½ COPD æ‚£è€…è‚ºé«˜å£“ |
| [3409916](https://pubmed.ncbi.nlm.nih.gov/3409916/) | 1988 | Journal Article | Eur Heart J | å…©å¹´ ID æ²»ç™‚å¯é•·æœŸæ¸›å°‘é–“è³ªæ€§è‚ºçº–ç¶­åŒ–æ‚£è€…çš„è‚ºé«˜å£“ |
| [7125407](https://pubmed.ncbi.nlm.nih.gov/7125407/) | 1982 | Comparative Study | Ann Intern Med | ISDN æ˜¯å”¯ä¸€èƒ½é™ä½åŸç™¼æ€§è‚ºé«˜å£“è‚ºå‹•è„ˆå£“çš„è—¥ç‰© |

æ–‡ç»è­‰æ“šé¡¯ç¤º ISDN å°å¤šç¨®é¡å‹çš„è‚ºé«˜å£“ï¼ˆåŒ…æ‹¬ COPD ç›¸é—œã€å¿ƒè¡°ç›¸é—œå’ŒåŸç™¼æ€§è‚ºé«˜å£“ï¼‰å‡æœ‰é™å£“æ•ˆæœã€‚

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. vascular disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypertrichosis (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. kyphoscoliotic heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. visceral calciphylaxis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. arterial thoracic outlet syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | å¯Œåˆ©å¿ƒèˆŒä¸‹éŒ ç­‰ | èˆŒä¸‹éŒ /éŒ åŠ‘ | é é˜²ç‹¹å¿ƒç—‡ç™¼ä½œã€å† ç‹€å‹•è„ˆä¸å…¨ã€å¿ƒçµç—› |

## å®‰å…¨æ€§è€ƒé‡

**å¸¸è¦‹å‰¯ä½œç”¨ï¼š**
- é ­ç—›ï¼ˆæœ€å¸¸è¦‹ï¼‰
- é ­æšˆ
- ä½è¡€å£“
- è‡‰éƒ¨æ½®ç´…
- å¿ƒè·³åŠ é€Ÿ

**ç¦å¿Œç—‡ï¼š**
- èˆ‡ PDE5 æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ sildenafilï¼‰ä½µç”¨ï¼šå¯èƒ½å°è‡´åš´é‡ä½è¡€å£“
- åš´é‡ä½è¡€å£“
- å³å¿ƒå®¤æ¢—å¡
- è‚¥åšæ€§å¿ƒè‚Œç—…è®Šä¼´æµå‡ºé“é˜»å¡

**é‡è¦è­¦å‘Šï¼š**
è‚ºé«˜å£“æ‚£è€…ä½¿ç”¨æ™‚å¯èƒ½å°è‡´å…¨èº«æ€§ä½è¡€å£“å’Œå¿ƒè¼¸å‡ºé‡ä¸‹é™ï¼Œéœ€è¬¹æ…ç›£æ¸¬ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é’å…‰çœ¼ (Glaucoma)** ğŸ”´ Major
- Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence...

**Cardiomyopathy, Hypertrophic** ğŸŸ¡ Moderate
- Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.

**Myocardial Infarction** ğŸŸ¢ Minor
- The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful cli...

**Anemia** ğŸŸ¢ Minor
- Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisonin...

**Diseases requiring hemodialysis** ğŸŸ¢ Minor
- The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The me...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
ISDN å°è‚ºé«˜å£“çš„æ²»ç™‚å…·æœ‰æ¸…æ™°çš„è—¥ç†æ©Ÿè½‰å’Œè±å¯Œçš„æ–‡ç»æ”¯æŒã€‚å¤šé …ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆé™ä½è‚ºå‹•è„ˆå£“åŠ›ã€‚ç„¶è€Œï¼Œå…¨èº«æ€§è¡€ç®¡æ“´å¼µä½œç”¨å¯èƒ½é™åˆ¶å…¶åœ¨å‰æ¯›ç´°è¡€ç®¡æ€§è‚ºé«˜å£“çš„æ‡‰ç”¨ã€‚ç›®å‰è‚ºå‹•è„ˆé«˜å£“çš„æ¨™æº–æ²»ç™‚å·²æœ‰æ›´é¸æ“‡æ€§çš„è—¥ç‰©ï¼ˆå¦‚å‰åˆ—ç’°ç´ é¡ä¼¼ç‰©ã€PDE5 æŠ‘åˆ¶åŠ‘ï¼‰ï¼ŒISDN å¯èƒ½æ›´é©åˆä½œç‚ºè¼”åŠ©æ²»ç™‚æˆ–ç‰¹å®šäºç¾¤çš„æ›¿ä»£é¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ˜ç¢º ISDN åœ¨ä¸åŒé¡å‹è‚ºé«˜å£“ä¸­çš„å®šä½
- èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚çš„æ¯”è¼ƒç ”ç©¶
- ç¢ºå®šæœ€ä½³çµ¦è—¥é€”å¾‘ï¼ˆå¸å…¥ vs å£æœ vs éœè„ˆï¼‰
- é•·æœŸå®‰å…¨æ€§å’Œè€å—æ€§æ•¸æ“š


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Isosorbide Dinitrateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/isosorbide_dinitrate/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_isosorbide_dinitrate,
  title = {Isosorbide Dinitrateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/isosorbide_dinitrate/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
